Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?"
As generative AI tools become commoditized and model capabilities increasingly turn into "public infrastructure," true differentiation no longer lies in whether one has AI, but in how seamlessly AI is integrated into a full closed-loop workflow-from target discovery and molecular generation to clinical validation. Drawing on Insilico Medicine's engineering practices and external partnerships with the Pharma.AI platform, Dr. Wang will share her perspectives on the competitive landscape in the "era of AI commoditization." She will highlight that data assets, automated experimental feedback loops, expert models, and tangible pipeline deliverables are the true keys to overcoming the commoditization trap. As Head of Global Business Development, she will also provide front-line insights into cross-border transactions and partnering models in AI-driven drug discovery.
About the China Healthcare Summit
Jointly hosted by BioCentury, BayHelix, and McKinsey & Company, the China Healthcare Summit has been held annually in Shanghai for more than a decade. It stands as one of the most influential international dialogue platforms in China's biopharmaceutical sector, as well as a prime venue for multinational pharmaceutical BD&L executives and investors seeking Chinese innovative assets. Covering licensing transactions, NewCo models, regulatory evolution, capital flows, market access strategies, and emerging Asian market opportunities (such as South Korea and Singapore), the summit serves as a vital window into China's life sciences ecosystem and the evolving global biopharma landscape.
November 4–5 | Shanghai
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Future Healthcare Investment Market (FHIM) annual conference at the Shanghai International Convention Center, where he will deliver a keynote address on the afternoon of November 4.
Focusing on AI-driven small molecule R&D practices, Dr. Ren will discuss how generative chemistry coupled with automated experimental loops significantly accelerates the journey from target to preclinical candidate (PCC). Drawing on several of Insilico's clinical-stage in-house programs, he will illustrate how AI platforms translate "technological advantages" into sustainable pipeline assets and transactable value propositions. Amid a more prudent global capital environment, he will also share actionable perspectives on how innovative drug developers can unlock and realize value through technological differentiation and business development partnerships.
About the 2026 Future Healthcare Investment Market (FHIM)
The Future Healthcare Investment Market is a premier industry gathering dedicated to bridging Chinese pharmaceutical innovation with global capital. Held on November 4–5 at the Shanghai International Convention Center, the conference convenes leading life sciences investment firms from Europe and China, multinational pharma BD leaders, and innovative biotech founders. Key topics include cross-border out-licensing and co-development of innovative drug assets, valuation frameworks for emerging technology platforms, and substantive deal-making facilitated through keynote speeches, panel discussions, and one-on-one partnering meetings.
November 5–10 | Shanghai
Insilico Medicine has once again been invited to exhibit at the China International Import Expo (CIIE), located at Booth C1-01, Hall 2.2. For this edition, Insilico is debuting holographic projection technology to present its R&D pipeline in three dimensions, intuitively deconstructing cutting-edge disease targets and innovative drug molecular conformations for an immersive, interactive tech experience.
Behind these booth highlights lies Insilico Medicine's robust pipeline momentum and platform translational capability. To date, within the first 10 months of 2026 alone, the company has nominated 11 preclinical candidates (PCCs)-setting a new historic annual record and bringing the cumulative total since 2021 to 35 PCCs. This track record demonstrates the breakthrough efficiency of generative AI through reproducible, real-world R&D outputs. Furthermore, as disclosed in the 2026 interim report, Insilico achieved 8 clinical milestones across its internal and partnered pipelines as of mid-August.
Among its numerous pipeline advances, Rentosertib (ISM001-055)-the world's first fully generative AI-discovered drug candidate with first-in-class potential-has officially entered Phase III clinical trials for idiopathic pulmonary fibrosis (IPF), marking a critical milestone in the final sprint toward definitive clinical benefit and commercialization.
About the 9th China International Import Expo (CIIE)
Co-hosted by the Ministry of Commerce of the People's Republic of China and the Shanghai Municipal People's Government, and organized by the China International Import Expo Bureau and the National Exhibition and Convention Center (Shanghai), CIIE partners with international bodies including the WTO, UNIDO, and ITC. It represents a major national initiative to proactively open China's market to the world. The 9th CIIE will take place from November 5 to 10, 2026, at the National Exhibition and Convention Center (Shanghai), covering an exhibition area of over 300,000 square meters. It features six major exhibition areas-Medical Equipment & Healthcare Products, Automobiles & Smart Mobility, Intelligent Industry & Information Technology, Consumer Goods, Food & Agricultural Products, and Trade in Services-alongside an Innovation Incubation Special Section, with the Hongqiao International Economic Forum held concurrently. The Medical Equipment & Healthcare Products exhibition area (Halls 1.1H, 1.2H, and 2.1H) introduces world-leading medical innovations, cutting-edge technologies, and services to support the Healthy China initiative and the silver economy.
November 6–8 | Nanchang
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Chinese Pharmaceutical Association Medicinal Chemistry Symposium (CMCS2026) in Nanchang. On the morning of November 7 at 11:00 AM, he will deliver a presentation titled: "Generative AI-Driven Innovative Drug Discovery and Clinical Advances."
From target discovery to molecular design and clinical-stage candidates, generative AI is reshaping the paradigm of medicinal chemistry. Dr. Ren will systematically elaborate on how Insilico Medicine leverages platforms such as PandaOmics and Chemistry42 to construct an end-to-end closed loop spanning target identification, de novo molecular generation, and automated experimental validation. He will also showcase the latest clinical progress of several AI-discovered targets and AI-designed molecules, exploring the essential hurdles generative AI must clear to transition from an "efficiency tool" to an "engine of original innovation," offering a front-line industry case study on the convergence of medicinal chemistry and artificial intelligence.
About the 2026 CPA Medicinal Chemistry Symposium (CMCS2026)
Organized by the Medicinal Chemistry Committee of the Chinese Pharmaceutical Association, CMCS is one of the most authoritative and influential academic conferences in China's medicinal chemistry community. Held from November 6 to 8, 2026, at the Primus Hotel Nanchang International Expo City (No. 1100 Shangrao Avenue, Honggutan District, Nanchang, Jiangxi Province), the symposium is themed "Multidisciplinary Convergence Driving Breakthroughs in Innovative Drugs." Renowned experts and scholars will gather across more than ten dedicated sessions, exploring new target discovery and validation, first-in-class therapeutics for major diseases, AI- and big data-driven smart drug discovery, medicinal chemical biology, green/efficient synthesis and scalable manufacturing, peptide/oligonucleotide/carbohydrate therapeutics, and ADCs/PDCs. Featuring plenary lectures, invited symposia, poster presentations, roundtable discussions, and a dedicated Young Scholars Forum, the conference aims to foster the sharing of cutting-edge research and facilitate seamless synergy between fundamental science and industrial translation.
November 7–10 | Dubai
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to attend the Next Generation Medicine Congress 2026 in Dubai. On the afternoon of November 7 at 5:00 PM, he will speak on a panel titled: "INVESTOR AND INNOVATOR PANEL."
During this direct dialogue between capital and technology, Dr. Aliper will draw upon an AI biotech's trajectory from technical proof-of-concept to a scaled pipeline, sharing how innovators can demonstrate enduring "platform capabilities" to investors rather than relying on a single narrative: reproducible wet-lab closed loops, consistently delivered clinical milestones, and an expanding partnership footprint together form the authentic competitive moat of an AI biotech company.
About the Next Generation Medicine Congress 2026
The Next Generation Medicine Congress is a premier international forum focused on translating cutting-edge medicine from evidence to real-world application. Taking place from November 7 to 10 in Dubai, the event convenes over 60 speakers and executive leaders from more than 20 countries across regenerative medicine, longevity medicine, precision healthcare, and healthcare investment. Under the theme "From Evidence to Adoption - Building the Clinic of 2030 Today," the congress explores clinical translation pathways, medical technology adoption frameworks, and healthcare investment trends, featuring a dedicated Investor and Innovator Panel to bridge the "last mile" from frontier medical breakthroughs to clinical and commercial realization.
New AI tool predicts hydrogen positions to speed up drug discovery